Purpose: Novel therapeutic approaches are needed to improve the postoperative management of residual nonfunctioning pituitary adenomas (NFPAs), given their high relapse rate. Here, we evaluated the antitumor efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in the only available model of spontaneous NFPAs (MENX rats).
Introduction
Pituitary adenomas account for 20% of all primary intracranial tumors (1) . They can be hormonally active or clinically nonfunctioning. Nonfunctioning pituitary adenomas (NFPAs) represent 30-35% of all pituitary adenomas and about 80% of them are gonadotropinomas (2) .
Transsphenoidal surgery is the main-stay treatment of patients with pituitary adenomas. Because of the lack of signs and symptoms secondary to hormone hypersecretion, NFPAs are often diagnosed late when they cause mass effects. At this stage, more than 40% of NFPAs are invasive (3) , so that complete surgical removal cannot be achieved. Reported recurrence rate varies between series, with up to 50% of patients experiencing long-term relapse (4, 5) . Management of patients with symptomatic residual and recurrent disease is challenging because no medical therapies are currently available. Radiotherapy remains the only post-operative option but it is not curative.
Chemotherapy is only used as salvage treatment but usually with disappointing results (6, 7) . Therefore, novel therapeutic approaches are required.
Activation of the PI3K/AKT/mTOR pathway plays a pivotal role in the initiation and progression of many human malignancies by enhancing cell survival, stimulating cell proliferation and inhibiting apoptosis (8, 9) . Constitutive activation of the PI3K/AKT/mTOR signaling cascade is also a feature of pituitary adenomas and is secondary to mutations or amplification of PI3KCA (10, 11) or to overexpression of PI3K (12) . NFPAs also display activation of the PI3K/AKT/mTOR pathway (13) . Thus, agents inhibiting PI3K signaling might represent an effective therapeutic option for these tumors. In support of this hypothesis, the mTOR inhibitor everolimus was reported to inhibit the viability of primary cultures of human NFPAs in vitro (14, 15) .
Several compounds have been generated to inhibit the PI3K/AKT/mTOR signaling cascade. The mTOR inhibitor rapamycin and its analogs (rapalogs) are currently used to treat several solid tumors (16, 17) . However, the development of drug resistance may limit their efficacy (18) . A well-documented mechanism of resistance to rapamycin and rapalogs is the activation of feedback loops on AKT which can re-activate the PI3K pathway (19) . To escape the feedback resistance, compounds able to inhibit both mTOR and the upstream PI3K kinase were generated, including NVP-BEZ235, a synthetic small molecule which inhibits both PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes (20) . NVP-BEZ235 has shown potent anti-proliferative activity in preclinical models of several tumor types (20) (21) (22) (23) (24) and is currently evaluated in Phase I/II clinical trials in patients with advanced solid tumors.
MENX is a multitumor syndrome in the rat caused by a biallelic loss-of-function mutation in Cdkn1b, encoding the cell cycle inhibitor p27 (25). MENX-affected rats (mutant) develop gonadotroph pituitary adenomas with complete penetrance and represent the only spontaneous model of such tumors. Rat adenomas closely resemble human NFPAs based on histological, immunohistochemical, and ultrastructural data, and are a suitable model for pharmacological studies of pituitary adenomas (26) (27) (28) .
Purpose of our study was to define the efficacy of PI3K/mTOR inhibition in NFPAs using the MENX rat model of spontaneous gonadotroph pituitary adenomas. We first assessed the effects of NVP-BEZ235 on 3D organotypic cultures of rat primary pituitary adenoma cells in vitro. Functional assays suggested that PI3K/mTOR inhibition promotes cytostatic but also cytotoxic effects on pituitary adenoma cells.
NVP-BEZ235 was then tested in vivo in affected rats. Molecular analyses in combination with functional imaging modalities (diffusion weighted-magnetic resonance imaging, DW-MRI) further pointed to a cytotoxic effect of NVP-BEZ235. DW-MRI emerged as a useful approach for early therapy monitoring of NFPAs following PI3K/mTOR inhibition. Expression array analyses identified the DEFB1 gene (encoding beta-defensin 1) as a novel mediator of PI3K blockade-dependent cell death and as a potential predictor of therapy response to PI3K inhibitors.
Materials and Methods

Compound preparation
NVP-BEZ235 was kindly supplied by Novartis Pharma. For in vitro studies, stock solutions of NVP-BEZ235 were prepared in 100% DMSO and stored at −20°C. Dilutions to the final concentration of 1µM were made in the culture medium immediately before use. For in vivo experiments, NVP-BEZ235 (45mg/kg, 30 mg/Kg, 20 mg/kg) was suspended in 1 volume of 1-methyl-2-pyrrolidone (Sigma Aldrich) and 9 volumes of PEG300 (Sigma Aldrich).
Primary pituitary adenoma cells from mutant rats were isolated as previously reported (26) and organotypic cultures were established using the 3D GravityPLUS™ (InSphero) system. Cells were seeded in a 96-well hanging drop culture platform (GravityPLUSTM, InSphero) in 3D InSight™ Cell Line Maintenance Medium (InSphero) to form spheroids. The spheroids were then transferred to a spheroid-specific 96-well microtissue receiver plate (GravityTRAPTM, InSphero) and further cultivated in the GravityTRAPTM plates. The spheres were analyzed in an inverted microscope and their size was estimated following treatment using a Hitachi camera HW/C20 installed in a Zeiss Axioplan microscope with Intellicam software (Carl Zeiss MicroImaging GmbH).
Immunostaining
Spheroids and pituitary tumor tissue from MENX rats were collected after 2 weeks of treatment with NVP-BEZ235 or placebo (PEG). They were fixed with 4% paraformaldehyde and embedded in paraffin. Immunohistochemistry (IHC) was performed on an automated immunostainer (Ventana Medical Systems) as previously described (27) . Primary antibodies were directed against monoclonal phospho (p)-S6 (S6-S240/244; 1:500; Cell Signaling), monoclonal p-AKT (Ser473; 1:75; Cell Signaling), monoclonal Ki67 (clone B56, 1:100; Dako), monoclonal p27 (1:100; BD Bioscience), polyclonal activated caspase-3 (1:100; Cell signaling), polyclonal αSU (1:1000; supplied by Dr.
Parlow, NHPP, UCLA). Antibodies were diluted in Dako REALTM antibody diluent (Dako). The SuperSentitive IHC detection system from BioGenex was used to visualize the antibody binding following the manufacturer's instructions. Images were recorded using a Hitachi camera HW/C20 (Hitachi) installed in a Zeiss Axioplan microscope with Intellicam software (Carl Zeiss MicroImaging).
For immunofluorescence (IF), we used the primary antibodies used for IHC and the antibody ab115813 against BD-1 (AbCam), and secondary anti-mouse Alexa Fluor® 555 Conjugate (Cell Signaling) or anti-rabbit FITC-conjugated (Invitrogen) antibodies (27) . Sections were then analyzed with a Zeiss Axiovert 200 epifluorescence microscope including Apotome unit (Carl Zeiss MicroImaging).
Quantification of P-S6 and cleaved caspase 3 (cc3) staining intensity was performed using Image-J (National Institutes of Health). Images were subjected to the threshold function and we used the 
Animals and in vivo treatment
This study was approved by the ethics committee on animal research of the government of Upper Bavaria, Germany. MENX-affected rats were maintained as previously reported (29) Three doses of NVP-BEZ235 were tested in MENX rats: 20, 30 and 45 mg/Kg. As the two higher doses caused a weight loss >10% after 10 days of treatment, the dose of 20mg/Kg was used for further studies. For MRI studies, MENX-affected rats at 7-8 months of age (with sizeable adenomas but still in good general health) were treated for 14 days with NVP-BEZ235 (20 mg/kg) or placebo (PEG) administered daily per oral gavage. The side effect of the drug we observed was mild diarrhea in the last days of the treatment (4/8 rats). Being this our first in vivo study of spontaneous rat pituitary adenomas, functional/molecular changes in the tumors were considered more objective and measurable end-points (primary end-points) compared to size and/or survival (secondary end-points).
Pathological analysis
Pituitary tumor tissues of PEG-or NVP-BEZ235-treated rats were fixed in 4% buffered formalin and paraffin-embedded. Three μm sections were cut and stained with hematoxylin and eosin (H& E), and were evaluated by an experienced neuropathologist (F.R.).
Magnetic resonance imaging
MRI was performed using a 3.0 Tesla clinical MRI system (Ingenia 3.0T, Philips Healthcare, Best, The Netherlands) prior and two weeks after treatment with NVP-BEZ235. Anesthetized animals (2.5 % isoflurane, administered in pure oxygen) were placed in a standard human wrist coil (SENSE Wrist coil 
RNA extraction
For RNA extraction from organotypic cultures, spheroids (n=30) were pooled and total RNA was extracted using the automated Maxwell 16 Cell Total RNA Purification Kit with the Maxwell 16 Instrument (Promega). From rat tissues, eight-micrometer sections of freshly prepared pituitary adenomas were stained with toluidine blue using standard manufacturer's protocols with minor modifications. The sections were air-dried and microdissected with a Leica AS LMD Laser Capture Microdissection System using laser pulses of 7.5 μm diameter, 20-40 mW, and with 2-3 ms duration (Leica). Laser captured tumor tissues were dissolved in 1-Thioglycerol/Homogenization Solution (Promega) and stored at -80°C. RNA extraction was performed as indicated above.
RT2 ProfilerTM PCR array and Quantitative TaqMan RT-PCR
For expression array analysis, the first strand cDNA synthesis was performed with the pooled mRNA from organotypic cultures using the RT² First Strand Kit (Qiagen). This cDNA was then added to the RT² SYBR Green qPCR Master Mix (Qiagen) and then each sample was onto the RT² Profiler™ PCR Array Rat Cell Death PathwayFinder (Qiagen). Real-time PCR detection was performed by heating the plate at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Data analysis was performed using the manufacturer's software (http://www.sabiosciences.com/ pcrarraydataanalysis.php).
Quantititative RT-PCR was performed using TaqMan inventoried primers and probes for the genes indicated in the article and for the rat beta 2-microglobulin gene, mouse beta 2-microglobulin gene or human TBP gene as internal controls (Applied Biosystem). The data were analyzed with 2 −ΔΔCt method as previously reported (28) .
Cell culture and transfection
Research.
on April 
Cell proliferation and apoptosis assays
Proliferation of BON1, QGP1 and αT3 cells after treatment was measured with the WST-1 colorimetric assay (Roche) as previously described (30) . Cell proliferation in 3D spheroids was measured with the CellTiter-Glo® Cell Viability Assay (Promega) according to the manufacturer's recommendations.
Apoptosis was measured by assessing the activity of caspase-3/7 using Caspase-Glo® 3/7 Assay kit (Promega). BON1 cells and QGP1 cells were transfected with scrambled or anti-DEFB1 siRNA as above, and 24 hrs later treated with NVP-BEZ235 or DMSO for additional 24 hrs. Caspase-3/7 activity was then assessed with a proluminescent caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD. Luminescence was measured with a luminometer (TECAN).
Statistical analysis
Results of the cell assays and Taqman analysis are shown as the mean of values obtained in independent experiments ± SEM. A paired two-tailed Student's t test was used to detect significance between two series of data, and P < 0.05 was considered statistically significant.
Results
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Organotypic cultures from three mutant rats (96 spheres each) were treated for two weeks with NVP-BEZ235 or DMSO. The surface area of 10 spheroids per culture was measured at the beginning and at the end of the treatment to assess their growth. A statistically significant reduction in size (-33%; P<0.001 versus DMSO control) (Fig. 1A) and a decrease in cell viability (-43%; P<0.01 versus DMSO control) ( Fig 1B) were observed in the spheroids treated with NVP-BEZ235 but not in those incubated with DMSO. Drug-treated 3D cultures showed both a dramatic decrease in P-S6 and reduced cell proliferation, as assessed by Ki67 staining (Fig. 1C) . Treatment of organotypic cultures with NVP-BEZ235 also induced the activation of caspase-3 (cleaved caspase 3, cc3) while no increase was seen in spheres treated with DMSO (Fig. 1C) . These experiments confirmed the inhibition of the PI3K/AKT/mTOR pathway by NVP-BEZ235 and its anti-proliferative and pro-cell death effects in vitro on NFPAs cells.
PI3K/mTOR inhibition reduces cell proliferation and promotes cell death in a model of endogenous NFPAs in vivo
To understand the effect of NVP-BEZ235 in spontaneous pituitary adenomas, we treated MENX rats with the drug. We first verified whether the drug reached the pituitary and repressed the PI3K pathway, as shown in vitro. NVP-BEZ235 (45mg/kg) or PEG (placebo) was administered to MENX rats (n=2 each group) by oral gavage and animals were sacrificed 1hr or 6hrs post-treatment.
Immunostains for P-AKT and P-S6 showed considerable reduction of the two proteins, and Fig. S2A ). In contrast, decrease in P-AKT and P-S6 was not significant at 1hr posttreatment ( Supplementary Fig. S2A ). The same tissues were also analyzed by Imaging Mass Spectrometry (MALDI Imaging). At 6hrs post-treatment, but not at 1h post-treatment, the pituitary adenomas of NVP-BEZ235-treated rats had a proteomic profile significantly different from the tumors of placebo-treated rats (Supplementary Fig. S2B ), thereby providing indirect evidence that the drug had reached the pituitary.
These results led us to treat mutant rats for two weeks with 20 mg/kg NVP-BEZ235 or PEG (placebo) both administered daily per oral gavage ( Fig. 2A) . At the end of the treatment, ex vivo tissue analysis showed that P-S6 expression and Ki67 labeling index (LI) were reduced in drug-treated pituitary adenomas and that cleaved caspase-3 (cc3) was increased (Fig. 2B) indicating efficacy of NVP-BEZ235 to inhibit PI3K/mTOR and to elicit multifaceted antitumor activities in NFPAs in vivo.
Quantification of the P-S6 and cc3 stainings and assessment of the Ki67 LI in the tumor tissues are shown in Figure 2D -E.
Pathological examination of NVP-BEZ235-treated adenomas (20mg/Kg) showed pronounced vacuolation of the cytoplasm when compared to PEG-treated animals ( Supplementary Fig. S3 ).
Vacuoles appeared even more prominent at the 30mg/Kg and 45mg/Kg doses ( Supplementary Fig.   S3 and data not shown). All treated tumors contained macrophages in variable number but none of them showed overt necrosis.
Diffusion weighted MRI shows a reduction in cellularity in NVP-BEZ235-treated rats
We then asked the question as to whether we can monitor the response to NVP-BEZ235 noninvasively in living MENX rats. Diffusion weighted magnetic resonance imaging (DW-MRI) with calculated mean apparent diffusion coefficient (ADC) values were used to assess changes in tumor cellularity (31) as indication of response to therapy. ADC values were obtained for all mutant rats (n=12) at day 0 (pre-therapy scans), and then 14 days after daily administration of 20mg/kg NVP-BEZ235 to a subset of animals (n=8), or of placebo (PEG) to the remaining ones (n=4) (post-therapy scans). Three sagittal center slices were used to calculate a mean ADC for each pituitary gland. As shown in Fig. 3 
Gene expression array analysis of NVP-BEZ235-treated 3D pituitary adenoma cultures identifies novel targets of the PI3K pathway
We then explored the molecular mechanisms mediating NVP-BEZ235-induced cell death in NFPAs.
We performed gene expression profiling of organotypic cultures derived from five independent rat pituitary adenomas following 2 weeks of treatment with NVP-BEZ235 or with DMSO. Genetic signatures were obtained using PCR-based arrays containing 84 cell death-related genes. By employing a >1.5 fold-change cut-off for gene expression changes, a total of 26 genes were found to be differentially expressed between the two groups. Twelve genes were up-regulated in drug-treated versus placebo-treated cells, and 14 genes were down-regulated ( Supplementary Fig. S4 ). Based on their functional annotation eleven including Foxi1, Defb1 and Tnfrsf8 were involved in necrosis.
Seven genes, including Tnfrsf10b, Cd40lg, Bcl2a1 were related to apoptosis and the remaining ones play a role in autophagy. (Fig. 4) . These in vivo data are consistent with those obtained analyzing pituitary adenoma organotypic cultures in vitro.
In conclusion, gene expression array analysis identified novel genes mediating the cytotoxic effect of PI3K/mTOR inhibition in NFPAs.
Defb1 is a target of PI3K/mTOR inhibition in pituitary adenomas and in other neuroendocrine tumor (NET) cells
Among the cell death-related genes induced by PI3K/mTOR inhibition in rat NFPAs, Defb1 is particularly interesting. This gene encodes beta-defensin 1 (BD-1), a member of a highly conserved group of host defence peptide (32) . Defensins play an important role in processes other than innate immunity (33) . In human cancers, BD-1 has been proposed to act as a tumor suppressor as it inhibits cell growth and promotes apoptosis (34-37). Currently, the extent of expression and role of DEFB1 in in NETs, and in pituitary adenomas in particular, is unknown.
For this reason, we determined the level of expression of DEFB1 in human NFPAs (n=6) by qRT-PCR and compared it with normal human pituitary tissues (n=3). The results showed that DEFB1 is extremely down-regulated in human NFPAs when compared with normal pituitary (Fig. 5A) . We also checked the expression of the BD-1 protein in human clinically nonfunctioning gonadotroph adenomas (n=10) by immunofluorescence. Only one out of 10 tumors showed weak expression while the others were negative (Fig. 5B) . In the normal human anterior pituitary, BD-1 was expressed and was found to colocalise with luteinizing hormone (LH) (Supplementary Fig. S5 ), indicating that BD-1 is expressed in normal gonadotroph cells and suggesting that BD-1 is lost in gonadotroph adenomas.
Next, we investigated the role of DEFB1 in NFPA by performing functional in vitro studies. Currently there are no established human/rodent NFPA/gonadotroph adenoma cell lines, so we tested αT3, a mouse immortalized gonadotroph cell line (38) . Similar to the rat primary adenoma cells, also αT3 cells showed an increase in beta-defensin 1 expression at both the mRNA and protein level (by immunofluorescence) upon NVP-BEZ235 treatment (Fig. 5C and D) . Concomitantly, a reduction in the levels of both P-AKT and P-S6 was observed in response to drug treatment (Fig. 5E) To verify whether BD-1 plays a more general role in NETs, we also analysed two well-characterized cell lines, BON1 and QGP1, both derived from human pancreatic endocrine tumors. Both cell lines express DEFB1 (Fig. 6C) . Similar to rat primary pituitary adenoma cells and mouse gonadotroph cells, also treatment of BON1 and QGP1 with NVP-BEZ235 induced the levels of both DEFB1 mRNA and BD-1 protein (Fig. 6A-C) . In agreement with previously published data (39), we observed that incubation with NVP-BEZ235 decreased the proliferation and increased the apoptosis of both cell lines, this latter assessed by measuring caspase 3/7 activity (Fig. 6D-G) .
We then wondered whether the induction of DEFB1 sensitizes NET cells to PI3K/mTOR inhibition.
Thus, we silenced DEFB1 expression by siRNA-mediated gene knockdown in BON1 and QGP1 cells and we then treated them with NVP-BEZ235. We could demonstrate that the knockdown of DEFB1 by specific si-DEFB1 molecules reduces the antitumor effect of the drug. Indeed, there was a more prominent decrease in cell proliferation ( Fig. 6D and F) and increase in apoptosis (caspase 3/7 activity) in cells transfected with unspecific scrambled siRNA than in cells transfected with si-DEFB1 ( Fig. 6E and G) . Efficient DEFB1 gene silencing was confirmed by qRT-PCR (Supplementary Fig.   S6 ).
Altogether, these data suggest that DEFB1 is a downstream target of the PI3KmTOR pathway in human NETs, where it mediates pro-apoptotic signals, and is a putative predictor of therapy response.
Discussion
We have previously shown that NVP-BEZ235 can potently inhibit cell proliferation of both dispersed rat primary pituitary adenoma cells and established adenoma cell lines in vitro (26) . Here, we expanded these studies to include organotypic cultures of rat primary pituitary tumors, better models of the situation in tissues. We demonstrated that drug treatment induces potent anti-proliferative and pro- 
antimicrobial peptide in epithelial tissues, BD-1 was recently found to be involved in a variety of processes other than innate immunity, including immunomodulation, development, wound healing and cancer (33) . In human cancers, BD-1 has been proposed to act as a tumor suppressor in renal clear cell carcinoma and prostate cancer since its expression is lower in the tumors compared with preneoplastic or normal tissues, and its ectopic overexpression induces caspase-3-mediated apoptosis (35, 37) . The mechanism of down-regulation of DEFB1 in the above tumors has not been fully elucidated, but methylation does not seem to play an important role (37). Consistent with these studies, we found that both DEFB1 and BD-1 are virtually not expressed in human NFPAs, suggesting that DEFB1 might represent a novel tumor suppressor gene in NFPAs. (50). PAX2 is expressed in the endocrine pancreas (from which BON1 and QGP1 cells derive) (51) but no information on the pituitary gland is available. Thus, we could envision a mechanism whereby inhibition of PI3K signalling in NET cells decreases PAX2 expression which in turn up-regulates DEFB1. Further studies are required to verify this hypothesis.
Bcl2a1/Bfl-1 was also among the genes differentially expressed in NVP-BEZ235-treated versus placebo-treated primary pituitary adenoma cells. In contrast to Defb1, its expression was reduced by the drug treatment in vitro and in vivo. Bfl-1 is an anti-apoptotic member of the Bcl-2 family of cell death regulators. In a physiological context, Bfl-1 is mainly expressed in the hematopoietic system, where it facilitates the survival of selected leukocytes subsets. Bfl-1 has been found overexpressed in a subset of chemoresistant tumors, where it protects tumor cells from chemotherapy-induced apoptosis (52) . Recently, peptide aptamers specifically targeting Bfl-1 have been generated and shown to sensitize B-cell lymphoma cell lines to chemotherapeutic drugs through induction of apoptosis (53, 54) . Given that NFPAs are usually resistant to traditional cytotoxic chemotherapeutic agents (2, 6), down-regulation of Bfl1 by NVP-BEZ235 might represent a useful strategy to sensitize these tumors to apoptosis induced by conventional chemotherapy. Altogether, our gene expression studies unveiled novel putative targets in NFPAs that deserve to be further evaluated for their therapeutic potential.
Of the several inhibitors of the PI3K signaling cascade, only everolimus (a mTOR inhibitor) has been so far evaluated in one patient with an aggressive pituitary tumor, specifically, with an ACTH-secreting pituitary carcinoma (55) . Everolimus was ineffective at normalizing hormone secretion and at controlling tumor growth. The lack of efficacy of everolimus could be ascribed to the well-documented feedback loop of rapalogs on AKT phosphorylation, already extensively associated with drug resistance in a variety of human cancers (18) . To overcome tumor cell resistance to these drugs, dual inhibitors have been developed that block mTOR but also the upstream PI3K kinase, such as NVP-BEZ235. Here we demonstrate that dual PI3K/mTOR inhibition is highly effective against 
